In these studies, we used the same gal-3 inhibitors that showed a robust effect on thioacetamide-induced liver fibrosis in rats [10] to evaluate their effect in a murine model of NASH. The gene discussed is LGALS3; the disease is metabolic dysfunction-associated steatohepatitis.